Principal Investigators
JANSSEN PHARMACEUTICA
Institution
JANSSEN PHARMACEUTICA
Contact information of lead PI
Country
Belgium
Title of project or programme
Biomarker based adaptive development in Alzheimer disease (BioAdaptAD)
Source of funding information
Flanders Innovation & Entrepreneurship
Total sum awarded (Euro)
2,241,280
Start date of award
01/06/2013
Total duration of award in years
4.0
The project/programme is most relevant to:
Alzheimer's disease & other dementias
Keywords
Research Abstract
The general objectives of this project are to develop a BACE inhibitor for disease modification in Alzheimer’s disease and to explore the development in an earlier prodromal Alzheimer’s disease population. From a drug development perspective, this will involve multiple adaptation steps and the intensive use of biomarkers.
Lay Summary
Further information available at:
Types: Investments > €500k
Member States: Belgium
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A